Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer
- 12 November 2011
- journal article
- review article
- Published by Elsevier in European Urology
- Vol. 61 (3), 549-559
- https://doi.org/10.1016/j.eururo.2011.11.009
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancerProstate Cancer and Prostatic Diseases, 2011
- Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trialAnnals of Oncology, 2011
- The association between radiographic response and overall survival in men with metastatic castration‐resistant prostate cancer receiving chemotherapyCancer, 2011
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration‐resistant nonmetastatic prostate cancerCancer, 2010
- Isolation of circulating tumor cells using a microvortex-generating herringbone-chipProceedings of the National Academy of Sciences, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Tumor–stroma co-evolution in prostate cancer progression and metastasisSeminars in Cell & Developmental Biology, 2009
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001